Co-delivery of doxorubicin and silybin via taurine-conjugated chitosan-modified TAUT-targeted liposomes enhances oral bioavailability and alleviates doxorubicin-induced cardiomyocyte toxicity in vitro.
Oral administration remains the most convenient and patient-preferred route for therapeutic drug delivery. However, the clinical translation of oral doxorubicin (DOX) is severely hampered by its low oral bioavailability, which remains a major challenge for oral chemotherapy. Herein, we report the development of taurine...